At 16 weeks, many saw significant itch relief. In a follow-up analysis, some saw itch relief as soon as 48 hours (9% with NEMLUVIO + topicals vs 3% with placebo). At 16 and 48 weeks, many saw clear or almost clear skin. Results may vary.

Not an actual patient.

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO^® (nemolizumab-ilto) is a prescription medicine used to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone.

Contraindication: Known hypersensitivity to NEMLUVIO or any ingredients in NEMLUVIO.

Warnings/Precautions: Hypersensitivity reactions have been reported with NEMLUVIO use. You should not receive a live vaccine right before or during treatment with NEMLUVIO.

Adverse Events: Most common side effects of NEMLUVIO include: headache, joint pain, hives (itchy red rash or wheals) and muscle aches.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/‌medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information including Patient Information.

©2025 Galderma Laboratories, L.P. All Rights Reserved.

NEMLUVIO is a registered trademark of Galderma.

US-NAD-2500004 11/25